~~<i id='15DB2C91B5'><strike id='15DB2C91B5'><tt id='15DB2C91B5'><pre id='15DB2C91B5'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

fashion

author：focus 2025-09-28 23:30:51 - browse：59

The FDA building -- First Opinion coverage from STAT — Adobe

WASHINGTON — The Food and Drug Administration’s top cancer drug regulator doesn’t always ask for permission before taking on big initiatives.

Richard Pazdur, director of the FDA Oncology Center of Excellence, hates bureaucracy. It stifles his ideas for getting treatments to cancer patients faster — of which there are many.

To cut through that bureaucracy, Pazdur has a trick: “Don’t tell anybody,” he said to laughter at a meeting of the advocacy group Friends of Cancer Research Tuesday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： FDA authorizes Novavax’s updated Covid

hotspot

entertainment

focus

entertainment

hotspot

Wikipedia

AdobeWhatwillhappenifAmericanslosetheconstitutionalrighttoabortion?Notallwomenwhoneedanabortionwould

WSS

Bristol 'take

How to increase colonoscopy rates? Looks like an AI can help

Ultragenyx gene therapy for rare liver ailment succeeds in late

Kaiser's Risant Health gobbled up Geisinger. Who is next?

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

FDA's Pazdur wants cancer trials to range beyond China alone

entertainment

fashion

hotspot

Drug repurposing or repositioning? The language matters

Bill would stop addiction treatment from triggering child abuse inquiry

Cancer drug shortages should be causing more outrage

HIV drugs protect against transmission, even in unprotected sex

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Liquid biopsy for lung cancer is launched by Delfi

As demand for Covid shots wanes, Moderna seeks its next success

Chemotherapy drug shortage eases slightly but still widespread

How to save PrEP access — and even expand it

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

entertainment

NIH documents show early flaws of $1.6 billion long Covid program

FDA's Pazdur wants cancer trials to range beyond China alone

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

FDA panel signals lack of confidence in Amgen cancer drug data

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

FDA rejects Alnylam's heart disease treatment over insufficient data

focus

entertainment

hotspot

Wikipedia